Abstract | BACKGROUND: METHODS: A systematic search of the available literature was performed using Medline, Embase, Cochrane Library and NHS Evidence databases, from inception to December 2017. The search terms used included: hereditary haemorrhagic telangiectasia (HHT), Osler-Weber-Rendu syndrome, epistaxis, haemorrhage and thalidomide. RESULTS: CONCLUSION: Current available evidence suggests that low-dose thalidomide is effective in transiently reducing epistaxis frequency and duration. Further studies are required to establish a treatment regimen to prevent side effects.
|
Authors | L Harrison, A Kundra, P Jervis |
Journal | The Journal of laryngology and otology
(J Laryngol Otol)
Vol. 132
Issue 10
Pg. 866-871
(Oct 2018)
ISSN: 1748-5460 [Electronic] England |
PMID | 30191780
(Publication Type: Journal Article, Review, Systematic Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Thalidomide
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage)
- Epistaxis
(drug therapy, etiology)
- Humans
- Recurrence
- Telangiectasia, Hereditary Hemorrhagic
(complications)
- Thalidomide
(administration & dosage)
- Treatment Outcome
|